A variety of organisms, such as bacteria, fungi, and plants, produce secondary metabolites,
also known as natural products. Natural products have been a prolific source and an …

Malaria accounts for an enormous burden of disease globally, with Plasmodium falciparum
accounting for the majority of malaria, and P. vivax being a second important cause …

Background The world has made great strides towards beating malaria, although about half
of the world population is still exposed to the risk of contracting malaria. Developing an …

In the last decade, there has been an upsurge of interest in developing malaria rapid
diagnostic test (RDT) kits for the detection of Plasmodium species. Three antigens …

Although there has been major recent progress in malaria vaccine development, substantial
challenges remain for achieving highly efficacious and durable vaccines against …

The resistance of malaria parasites to existing drugs carries on growing and progressively
limiting our ability to manage this severe disease and finally lead to a massive global health …

Background GMZ2 is a recombinant protein malaria vaccine, comprising two blood-stage
antigens of Plasmodium falciparum, glutamate-rich protein and merozoite surface protein 3 …

Plasmodium parasites are the causative agent of human malaria, and the development of a
highly effective vaccine against infection, disease and transmission remains a key priority. It …

Malaria is a life‐threatening disease caused by parasites of the P lasmodium genus. In
many parts of the world, the parasites have developed resistance to a number of antimalarial …

Background GMZ2 is a recombinant malaria vaccine inducing immune responses against
Plasmodium falciparum (Pf) merozoite surface protein-3 and glutamate-rich protein. We …